VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRLA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRLAIRulya Therapeutics Inc.
$40.59$39M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. IRLA
  4. Financial Ratios

IRulya Therapeutics Inc. (IRLA) Financial Ratios

Latest Ratios: P/E Ratio -4.6x · EV/EBITDA N/A · ROE N/A. (2017–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

IRLA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$487M$168M$81M$39M$21M$375M$811M$1.1B——
Enterprise Value$500M$180M$89M$32M$-22788666$306M$744M$1.0B——
P/E Ratio →-4.56—————————
P/S Ratio——————————
P/B Ratio——2.680.460.213.164.719.25——
P/FCF——————————
P/OCF——————————

P/E links to full P/E history page with 30-year chart

IRLA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue——————————
EV / EBITDA——————————
EV / EBIT——————————
EV / FCF——————————

IRLA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin——————————
Operating Margin——————————
Net Profit Margin——————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE——-98.6%-33.8%-47.1%-61.9%-53.4%-39.6%-48.8%—
ROA-80.7%-80.7%-38.6%-22.1%-43.6%-55.7%-49.0%-37.5%-31.0%-158.5%
ROIC-482.0%-482.0%-73.5%-38.6%-73.3%-86.9%-69.6%-53.0%-69.7%—
ROCE-64.0%-64.0%-41.2%-25.5%-47.3%-62.0%-54.8%-41.9%-31.3%-174.1%

IRLA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity——0.490.160.000.010.00———
Debt / EBITDA——————————
Net Debt / Equity——0.29-0.08-0.44-0.58-0.39-0.44-0.35—
Net Debt / EBITDA——————————
Debt / FCF——————————
Interest Coverage————-90.12———-12.04-6.31

IRLA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio0.530.536.058.0930.557.858.1111.9349.824.28
Quick Ratio0.530.536.058.0930.557.858.1111.9349.824.28
Cash Ratio0.410.415.607.8429.387.517.8711.2349.224.17
Asset Turnover——————————
Inventory Turnover——————————
Days Sales Outstanding——————————

IRLA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield——————————
Payout Ratio——————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield——————————
FCF Yield——————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$250485$216311$186186$167483$148593$145881$95160$107756$107756

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Capital Returns Remain Deeply Negative

As reported in recent financial statements, QNCX has consistently generated negative ROIC, with figures reaching -80.6% in 2025Q3, reflecting the company's inability to deploy capital effectively across its shifting clinical pipeline while struggling to achieve any meaningful return on its historical investments in research and development.

The persistent negative ROIC suggests that the company's capital allocation has been value-destructive, as the firm continues to burn through resources without achieving clinical milestones that would justify the expenditure. Investors should monitor whether the pivot to the bone-targeting platform can eventually reverse this trend, though current data indicates a long path to positive capital efficiency.

Liquidity Buffer Faces Severe Pressure

Based on the 2026Q1 balance sheet, the company's current ratio of 2.92 appears deceptively stable, yet this metric masks a precarious cash position that, according to historical burn rates, leaves the firm highly vulnerable to clinical trial cost overruns and the urgent need for dilutive external financing.

While the current ratio suggests a degree of short-term coverage, the lack of revenue generation means that liquidity is entirely dependent on the remaining cash balance. Any delay in clinical progress or unexpected regulatory hurdles could rapidly exhaust these resources, leaving the company with limited options for survival outside of further equity dilution.

Debt Obligations Remain Highly Volatile

According to historical financial data, QNCX's debt-to-equity ratio has fluctuated wildly, peaking at 16.99 in 2025Q3, which indicates that the company's capital structure is heavily influenced by non-operational financing activities rather than a sustainable or predictable approach to managing long-term debt obligations or interest coverage.

The extreme volatility in leverage ratios suggests that the company's balance sheet is not managed for operational stability but rather for survival through intermittent capital raises. This lack of consistent leverage management warrants caution, as it implies that the firm's financial health is subject to the whims of capital markets rather than internal cash generation.

Misapplication of Traditional Valuation Multiples

As indicated by the company's current financial profile, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for QNCX, as these metrics obscure the reality that the firm is a pre-revenue entity whose value is derived entirely from speculative clinical assets rather than current earnings.

Investors should instead focus on cash-burn-adjusted valuation metrics or the potential net present value of the bone-targeting platform's pipeline. Relying on traditional multiples in this context risks misinterpreting the company's financial distress as a valuation discount, when in reality, the metrics are simply not applicable to a business model that lacks commercial operations.

Download Financial Ratios Data

Includes 30+ ratios · 9 years · Updated daily

Consensus & Technical Research Suite
Open IRLA Terminal

IRLA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

IRLA — Frequently Asked Questions

Quick answers to the most common questions about buying IRLA stock.

What is IRulya Therapeutics Inc.'s P/E ratio?

IRulya Therapeutics Inc.'s current P/E ratio is -4.6x. This places it at the 50th percentile of its historical range.

Is IRLA stock overvalued?

Based on historical data, IRulya Therapeutics Inc. is trading at a P/E of -4.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.